HEMATOLOGICAL ADVERSE EVENTS ON THE BACKGROUND OF ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C

Abstract. Currently, the main etiotropic method of treating chronic hepatitis C is combination therapy with standard interferon-a (IFN-a) or pegylated interferon-a (PIFN-a) in combination with ribavirin. Despite significant advances in AVT in CHC patients, adverse events may occur during treatment, which force either to reduce the dosage of drugs or stop treatment altogether.

Перевод пока недоступен